Establishment Labs Announces Events for Pink October and Breast Cancer Awareness Month
SANTA BARBARA, California, September 30, 2021– (BUSINESS WIRE) – Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving the health and well-being of women, primarily in the aesthetics and reconstruction of the breast, today announced events and activities planned for the month of October in support of Pink October and Breast Cancer Awareness Month.
“One in eight women will develop breast cancer in her lifetime. Although survival rates have improved, the disease can still have a devastating impact on the lives of these women, ”said Juan José Chacón-Quirós, founder and CEO of Establishment Labs. . “For women requesting breast reconstruction surgery, availability remains tragically low, with less than 10% of women worldwide receiving reconstruction after mastectomy and wait times in some countries up to eight years. At Establishment Labs, supporting efforts to improve access and provision of the tools necessary to improve outcomes is our mission as a women’s health company. “
As part of Pink October, Establishment Labs will once again support its annual Pink is for Power breast reconstruction program in Brazil. This year, the company, in partnership with plastic surgeons and hospitals in more than 20 cities in Brazil’s five regions, will provide the necessary resources to enable 200 women to benefit from breast reconstruction surgery. “Being diagnosed with cancer is a very frightening time in any person’s life, and the journey to recovery takes a lot of strength and determination,” added Mariana Bonatto, Business Director of Etablissement Labs Brazil. “Our goal with the Pink is for Power campaign is to help these women recover because we believe that reconstruction goes far beyond surgery and has a direct impact on patients returning to their lives.”
“While our breast reconstruction support is present year round, we have several special events for Pink October,” continued Heather Brennan, US Business Operations Manager. “These include our annual Rosé for Reconstruction event at the Sixth Global Symposium on Ergonomic Implants in Gardone Riviera, Italy, where we will announce funding for an annual Scott Spear Memorial Grant to support research, education and advocacy for breast reconstruction. We’re also launching our partnership with the International Chess Federation, where Establishment Labs sponsors women’s chess events through 2022, including the Women’s World Team Championship being held this week in Sitges, Spain. Our support for women’s chess since 2017 further underscores our commitment to women in all aspects of life. We believe empowered women who make smart choices are beautiful. “
“October is the time to raise awareness and better understand breast cancer; however, as a global women’s health medical device company, Establishment Labs has a unique and important responsibility to bring to market technologies that can improve clinical and aesthetic outcomes, ”concluded Rosalyn Cole of Incelli, responsible for global regulatory and clinical affairs. “The recent launch of our Motiva Flora® tissue extender is the first step in a program we call Aesthetic Breast Recon®, where Establishment Labs offers tools and techniques that enable women to undergo reconstructive surgeries that achieve the aesthetic ideals they aspire to. We believe our innovations, in partnership with breast reconstruction surgeons, will set new standards for post-mastectomy outcomes and further turn breast cancer into a treatable disease from which women can fully recover. “
Among the events sponsored by Establishment Labs in October:
All month: Pink is For Power Breast reconstruction support; Brazil
October 1: Motiva Breast Health Day; Barcelona, Spain
October 2-3: Sponsorship of the Women’s World Team Championship of the International Chess Federation (FIDE); Sitges, Spain
October 15: Rosé for Reconstruction; Riviera of Gardone, Italy
October 20: Breast reconstruction awareness day and Patient education day; Virtual
About establishment laboratories
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving the health and well-being of women. The initial focus of the business is breast health, primarily aesthetics and breast reconstruction. Establishment Labs offers a line of advanced silicone gel-filled breast implants under the Motiva Implants brand.® which include a number of innovative and patented features designed to improve aesthetic and clinical results. Since the commercial launch in 2010, more than 1.6 million Motiva implants® have been delivered to plastic surgeons in more than 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an Investigational Device Exemption (IDE) from the FDA for the Motiva implant® and began a clinical trial to support regulatory approval in the United States. Motiva implants® are manufactured at the company’s two factories in Costa Rica, which comply with all applicable regulatory standards under ISO13485: 2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for more information at www.establishmentlabs.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many of these statements (but not all) by searching for words such as “approximate”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “Plans”, “the intention of,” “would”, “will”, “could” or other similar expressions in this press release. Factors, among others, that could cause the results and events to be Realities differ materially from those described in forward-looking statements include risks and uncertainties relating to: our ability to develop, seek and obtain successful, timely and cost-effective regulatory approval to market our product offerings; adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and t the allocation of capital; our ability to develop and / or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid significant disruption to our supply chains; our ability to attract and retain key personnel; our ability to evolve our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. Any statement that refers to projections of our future financial or operational performance, anticipated trends in our business, our objectives, strategies, priorities and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the performance of the company are forward-looking statements. We claim the safe harbor protection contained in the Private Securities Litigation Reform Act of 1995. We caution investors that all forward-looking statements made in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on information currently available at the time these statements are made. Such statements are based on assumptions, and actual results will be affected by known and unknown risks, trends, uncertainties and factors which are beyond our control. Although we believe our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be inaccurate. Therefore, our actual future results and the timing of events may differ from our expectations, and these differences may be material. Factors that could cause or contribute to these differences include, among others, the risks and uncertainties discussed in the company’s annual report on Form 10-K filed on March 15, 2021, the quarterly reports on Form 10-Q and d ‘other documents filed by the company with the Securities and Exchange Commission. The risks included in these documents are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is impossible for us to predict all of these risk factors, nor to assess the impact of all of these risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in forward-looking statements. We assume no obligation to update any forward-looking statements. Therefore, investors should exercise caution in relying on past forward-looking statements, which are based on results and trends known at the time they are made, to anticipate future results or trends.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210930005901/en/
Investor / media contact: